Biotechnology firm Epistem has delivered steady full-year results, while also accelerating investment in a number of its core development programmes.
Total sales of £5.6m (2011: £5.8m) were driven by a solid performance by Contract Research Services and strong growth in its Personalised Medicine division. The latter delivered more than 100% year-on-year growth, following collaborations with GlaxoSmithKline, Sanofi-Aventis and emerging sales of its Genedrive diagnosis machine.
There has been ongoing investment in its Novel Therapies lead programme and its Diagnostics (Genedrive) programmes. This was the reason it gives for moving into a pre-tax loss of £720,000 from a profit of £357,000.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
A successful £2.7m cash placing, led to a strengthened cash balance of £4.7m at June 30th.
Consensus forecasts for the year ending June 30th 2013 are for a pre-tax loss of £270,000 on turnover of £6.98m.
CM
-
The industry at the heart of global technologyThe semiconductor industry powers key trends such as artificial intelligence, says Rupert Hargreaves
-
What are shareholder voting rights and why do they matter?If you hold shares in a company, the chances are they’ll come with voting rights. But how do you exercise your right to vote? And is your fund manager taking it seriously?
